U.S. Markets closed

Mustang Bio, Inc. (MBIO)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.8800+0.1100 (+3.97%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.7700
Open2.7400
Bid2.8900 x 3100
Ask2.9400 x 3200
Day's Range2.7400 - 2.9000
52 Week Range2.4200 - 5.2200
Volume1,400,620
Avg. Volume1,230,112
Market Cap251.462M
Beta (5Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)-1.0150
Earnings DateMar 24, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.40
  • GlobeNewswire

    Mustang Bio to Participate in Three September 2021 Investor Conferences

    WORCESTER, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in September 2021. Details of the events are as follow

  • GlobeNewswire

    Mustang Bio Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights

    WORCESTER, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2021. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “In

  • Benzinga

    Mustang Bio, Mayo Clinic Join Forces On New CAR T Tech In Tumor Settings

    Mustang Bio Inc (NASDAQ: MBIO) executed an exclusive license agreement with Mayo Clinic for a new approach to administering chimeric antigen receptor engineered T cell (CAR T) therapies and potentially be used as an off-the-shelf therapy. The technology uses a two-step approach. First, a peptide is administered to drive the proliferation of the patient's resident T cells. Then a viral CAR construct is administered directly into the lymph nodes of the patient. In turn, the viral construct infects